Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.

[1]  S. Jagannath,et al.  Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. , 2022, The New England journal of medicine.

[2]  N. Geller,et al.  Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma , 2022, American journal of hematology.

[3]  S. Dusetzina.  Your Money or Your Life - The High Cost of Cancer Drugs under Medicare Part D. , 2022, The New England journal of medicine.

[4]  H. Jim,et al.  Self-efficacy for Symptom Management in Long-term Adult Hematopoietic Stem Cell Survivors. , 2022, Transplantation and cellular therapy.

[5]  Samiksha Gupta,et al.  Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high‐risk cytogenetics: A meta‐analysis of randomized controlled trials , 2022, Cancer.

[6]  M. V. D. van den Brink,et al.  Nutrition perceptions, needs and practices among patients with plasma cell disorders , 2022, Blood Cancer Journal.

[7]  G. Muto,et al.  Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational study , 2022, Minerva Urology and Nephrology.

[8]  K. Anderson,et al.  Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma , 2022, Cancer.

[9]  Jung-Yi Lin,et al.  Evaluating Race and Time to Transplantation in Multiple Myeloma: The Mount Sinai Hospital Experience. , 2021, Clinical lymphoma, myeloma & leukemia.

[10]  C. Ade,et al.  Health behaviors and patient–practitioner communication in cancer patients and the general population: an analysis of the National Health and Nutrition Examination Survey (NHANES) 2005–2014 , 2021, Supportive Care in Cancer.

[11]  Catherine S. Y. Lecat,et al.  Multiple myeloma and physical activity , 2020, BMC Research Notes.

[12]  N. Munshi,et al.  Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial , 2020 .

[13]  A. Dispenzieri,et al.  Financial Toxicity and Impact on Health-Related Quality of Life in Patients with Plasma Cell Disorders , 2020 .

[14]  P. Hari,et al.  Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma , 2020, Cancer.

[15]  A. Hackshaw,et al.  Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design , 2020, British Journal of Cancer.

[16]  R. Chakraborty,et al.  Treatment and disease‐related complications in multiple myeloma: Implications for survivorship , 2020, American journal of hematology.

[17]  P. Moreau,et al.  Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma , 2020, Leukemia & lymphoma.

[18]  E. Tholouli,et al.  Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Purushottam W. Laud,et al.  Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors , 2018, Haematologica.

[20]  J. Hardin,et al.  Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry , 2018, Annals of Hematology.

[21]  Shaji K. Kumar,et al.  Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  P. Hari,et al.  Current Use and Trends in Hematopoietic Cell Transplantation in the United States. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  W. Wood,et al.  Cancer and treatment distress psychometric evaluation over time: A BMT CTN 0902 secondary analysis , 2017, Cancer.

[24]  N. Munshi,et al.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.

[25]  E. Lahelma,et al.  The association between alcohol drinking and self-reported mental and physical functioning: a prospective cohort study among City of Helsinki employees , 2017, BMJ Open.

[26]  W. Wood,et al.  Can we agree on patient-reported outcome measures for assessing hematopoietic cell transplantation patients? A study from the CIBMTR and BMT CTN , 2016, Bone Marrow Transplantation.

[27]  S. Langer,et al.  Psychometric properties of the Cancer and Treatment Distress (CTXD) measure in hematopoietic cell transplantation patients , 2016, Psycho-oncology.

[28]  W. Leisenring,et al.  Factors associated with adherence to preventive care practices among hematopoietic cell transplantation survivors. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  J. Teresi,et al.  The Cornell Service Index as a measure of health service use. , 2005, Psychiatric services.

[30]  J. Ware,et al.  A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. , 1996, Medical care.